The National Organization for Rare Disorders (NORD®) is honoring a distinguished group of industry leaders and individuals for their contributions to help improve the lives of more than 30 million ...

BeOne Medicines has secured approval from the EC for Tevimbra (tislelizumab) to be used along with gemcitabine and cisplatin to treat NPC.

The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...

The Idiopathic Thrombocytopenic Purpura market is poised for significant expansion through 2032, underpinned by rising disease awareness, improving epidemiological understanding, and a vibrant ...

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in ...

Watching other people tuck into tasty food may trigger overeating, suggests new research. Seeing others enjoying a good feed ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The authors investigated the potential role of IgG N-glycosylation in Haemorrhagic Fever with Renal Syndrome (HFRS), which may offer significant insights for understanding molecular mechanisms and for ...

Discover what glycan analysis can reveal about protein behavior and how it can be used to boost biologic performance and ...